ReCode Therapeutics
6 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance (NCT06633757) | ReCode Therapeutics | 2024-10-22 |
| A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD (NCT06600425) | ReCode Therapeutics | 2024-09-20 |
| A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF (NCT06237335) | ReCode Therapeutics | 2024-02-01 |
| A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials (NCT06172374) | ReCode Therapeutics | 2023-08-31 |
| A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults (NCT05685186) | ReCode Therapeutics | 2023-03-08 |
| Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects (NCT05737485) | ReCode Therapeutics | 2023-02-18 |
Track ReCode Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.